Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.47 – $1.64
Volume9,429
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.24M
Price / earnings
—
Price / book
-6.12×
Price / sales
34.65×
EV / sales
34.75×
EV / EBITDA
-0.25×
Profitability
Earnings per share
-$6.98
Return on assets
-247.39%
Return on equity
2,513.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-4.18×
Current ratio
0.66×
Quick ratio
0.62×
Cash ratio
0.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.25M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JUNS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.25K
$18.65K
$21.8K
$0
$0
$0
$0
Cost of revenue
$3.18K
$4.36K
$4.23K
$0
$0
$0
$0
Gross profit
$21.06K
$14.29K
$17.57K
$0
$0
$0
$0
Selling, general and administrative
$2.16M
$1.57M
$2.78M
$1.48M
$1.51M
$1.07M
$1.26M
Research and development
$600.35K
$411.05K
$43.68K
$816.7K
$759.45K
$466.75K
$201.01K
Total operating expenses
$2.76M
$1.98M
$2.83M
$2.3M
$2.26M
$1.54M
$1.46M
Operating income
-$2.74M
-$1.96M
-$2.81M
-$2.3M
-$2.26M
-$1.54M
-$1.46M
Interest expense
-$90.62K
-$118.64K
-$62.46K
-$1.19K
-$1.14K
-$1.23K
-$30.55K
Income before taxes
-$2.27M
-$2.06M
-$2.58M
-$2.29M
-$2.25M
-$1.53M
-$1.53M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.27M
-$2.06M
-$2.58M
-$2.29M
-$2.25M
-$1.53M
-$1.53M
Net income attributable to common shareholders
-$2.27M
-$2.06M
-$2.58M
-$2.29M
-$2.25M
-$1.53M
-$1.53M
EBITDA
-$2.55M
-$1.77M
-$2.62M
-$2.1M
-$2.07M
-$1.35M
-$1.4M
Basic earnings per share
-$4.08
-$4.50
-$5.06
-$5.25
-$5.09
-$3.75
-$3.82
Diluted earnings per share
-$4.08
-$4.50
-$5.06
-$5.25
-$5.09
-$3.75
-$4.25
Recent news
Company coverage with links to the original publishers.
Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on CNS disorders and neuroinflammation, announced a registered direct offering of 7,142,858 shares of common stock for approximately $2.0 million gross proceeds. The offering is expected to close on May 21, 2026, with D. Boral Capital LLC serving as the exclusive placement agent.
Jupiter Neurosciences (NASDAQ: JUNS) announced a webinar on January 6, 2026, where CEO Chister Rosén will discuss the company's JOTROL™ resveratrol platform, upcoming Phase 2a Parkinson's disease trial, and commercialization of its Nugevia™ consumer product line. The company is pursuing a dual-path strategy combining pharmaceutical development with consumer longevity products.
Jupiter Neurosciences announced a significant advancement in resveratrol technology with JOTROL™, achieving nine-fold increased bioavailability and reduced gastrointestinal side effects, with potential applications in neurodegenerative disease treatment and consumer supplements.
Jupiter Neurosciences announced the launch of Nugevia, a new consumer longevity supplement line powered by its patented JOTROL delivery platform. The company has partnered with professional golfer Annika Sörenstam as the brand ambassador for Nugevia.
Jupiter Neurosciences, a clinical-stage pharmaceutical company, has announced the closing of its $11 million initial public offering. The company plans to use the proceeds to fund a Phase II clinical trial for its product candidate JOTROL™ in Parkinson's Disease, as well as for other research and development activities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.